Moderna's stock doubles after successful cancer vaccine trial
On August 19, 2026, Moderna (NASDAQ: MRNA) saw its shares nearly double following positive results from a clinical trial of its experimental cancer vaccine. The biotech sector was lifted by the news as investors reacted positively to the potential breakthrough in oncology treatments. The broader stock market also experienced gains after the U.S. Treasury announced plans to more than double the size of its debt buybacks, which helped stabilize government bond markets following a prior selloff. Additionally, President Donald Trump paused new 50% tariffs on Canadian imports just before they were set to take effect. Market analysts noted that rising long-term bond yields and concerns over inflationary pressures from large-scale AI investments are creating structural tensions in financial markets. Despite these challenges, investors remain optimistic about future returns driven by high-growth sectors like biotechnology.
Tickers: $MRNA